Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lexicon

- PMLiVE

Diabetes rates jump by 60% in UK

Comes as new analysis also reveals that 10% of the NHS GP drugs budget spent on the disease

- PMLiVE

Healthcare gets more independence in Google restructuring

New ‘Alphabet’ company will put tech giant’s health ventures centre-stage

- PMLiVE

Diabetes costs jump again in England

Cost of treating the disease rising as prices and patients increase in number

Sanofi reception

Sanofi and Evotec to work together on diabetes and cancer

Willfocus on beta cell-modulating diabetes treatments and immuno-oncology therapies

Boehringer Ingelheim headquarters

Boehringer returns to growth in first half

German firm back on track after a tough sales period

Sanofi reception

Sanofi keeps Toujeo price level with Lantus in UK

French firm hoping to maintain market share with its next-gen insulin product

Lilly brings Glucagon app to Android devices

Follows app's 2012 debut in iPhone version

- PMLiVE

Merck hopes for another Keytruda with new immunotherapy deal

US firm signs pact with cCAM Biotherapeutics for cancer research

Sanofi reception

Sanofi and Regeneron extend partnership to cancer

Sanofi will pay more than $2bn to the firm for immunotherapy research

- PMLiVE

Sanofi’s cholesterol drug Praluent backed for European approval

CHMPdecision puts firm on-course to catch up with Amgen's Repatha

- PMLiVE

FDA approves four new medicines across multiple areas

Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals

AstraZeneca AZ

AZ sells rare cancer drug to Sanofi

French firm’s rare disease unit Genzyme will pay $300m for the treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links